The PA will play a key role in the evaluation and longitudinal management of patients with Alzheimer’s disease and related dementias, including those enrolled in the Alzheimer Therapeutics Program receiving disease-modifying anti-amyloid therapies.
Base: $122,803.20 - $173,867.20/Annual; Bonus/Equity: Not specified; Benefits: Comprehensive benefits
Must-have
Nice-to-have
Not specified